NCT05082662View on ClinicalTrials.gov

Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated Tablet

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 25, 2020

Primary Completion Date

September 16, 2020

Study Completion Date

September 16, 2020

Conditions
Non-steroidal Anti-inflammatory (NSAID)AnalgesicAntipyretic
Interventions
DRUG

Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium)

One Diclofenac tablet was administered orally.

DRUG

Cataflam® 50 coated tablet

One Diclofenac tablet was administered orally.

Trial Locations (1)

Unknown

ACDIMA Biocenter, Amman

All Listed Sponsors
lead

Humanis Saglık Anonim Sirketi

INDUSTRY

NCT05082662 - Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet Versus Cataflam® 50 Coated Tablet | Biotech Hunter | Biotech Hunter